Daniel Danila

7PUBLICATIONS
80CO-AUTHORS
Predictive and prognostic markersPharmaceutical delivery technologies
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Apr 01, 2026
Cytoplasmic versus nuclear localization of androgen receptor splice variant 7 as a predictor of benefit from androgen receptor pathway inhibitors in metastatic castration-resistant prostate cancer (PROPHECY trial).

Santosh Gupta, Siyuan Guo, Susan Halabi

|Mar 18, 2026
Genomic Features and Response to Poly(ADP-ribose) Polymerase Inhibition in Metastatic Castration-Resistant Prostate Cancer.

Jeffery C W Chang, Subhiksha Nandakumar, Konrad H Stopsack

|Jul 01, 2024
Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate Cancer.

Andrew T Lenis, Vignesh Ravichandran, Samantha Brown

|Jan 18, 2024
The Impact of Circulating Tumor Cell HOXB13 RNA Detection in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide.

Susan Halabi, Siyuan Guo, Joseph J Park

|Oct 20, 2023
Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study.

William K Kelly, Daniel C Danila, Chia-Chi Lin

|Mar 10, 2023
PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer.

Santosh Gupta, Susan Halabi, Qian Yang

Pageof 2

Frequent Collaborators

4 joint publications

Andrew J Armstrong

4 joint publications

Susan Halabi

3 joint publications

Jun Luo

3 joint publications

Russell Zelig Szmulewitz